3 completed, 3 recruiting. 2 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Alebund Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 2 | Recruiting | R1 Therapeutics | 168 | 2026-06-01 | 2026-08-26 |
| A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China AP301, AP301 Low Dose - Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis | Phase 3 | Recruiting | Alebund Pharmaceuticals | 264 | 2025-06-13 | 2026-01-29 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients AP303 150μg, Placebo 150μg - Diabetic Kidney Disease | Phase 1 | Recruiting | Alebund Pharmaceuticals | 18 | 2025-02-27 | 2025-09-11 |
| A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants AP303 150 μg, Placebo 150 μg, AP303 300 μg - Healthy Subjects | Phase 1 | Completed | Alebund Pharmaceuticals | 18 | 2024-03-18 | 2024-10-22 |
| AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose - ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Completed | Alebund Pharmaceuticals | 474 | 2023-06-12 | 2025-11-17 |
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
Hyperphosphatemia (4) · Renal Insufficiency, Chronic (3) · Diabetic Nephropathies (1)
Sevelamer (2) · BID protein, human (1)
China (6) · United States (2)
Hong Zhang (1) · Li Wang, MD (1) · Ying Gao (1)